# EDGAR Filing Document

**Accession Number:** 0001130166
**File Stem:** 0001493152-25-014840
**Filing Date:** 2025-9
**Character Count:** 8047
**Document Hash:** b1a4a3e85eee71529f7eabddc3b0da65
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-014840.hdr.sgml**: 20250925

**ACCESSION NUMBER**: 0001493152-25-014840

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250919

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250925

**DATE AS OF CHANGE**: 20250924

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bio Green Med Solution, Inc.
- **CENTRAL INDEX KEY:** 0001130166
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911766850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50626
- **FILM NUMBER:** 251339873

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 908-517-7330

**MAIL ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cyclacel Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20060329

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCYTE THERAPIES INC
- **DATE OF NAME CHANGE:** 20001218

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**September 19, 2025**

Date of Report (date of earliest event reported)

![](form8-k_001.jpg)

**Bio Green Med Solution, Inc.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-50626** | **91-1707622** |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification Number) |

---

**Level 10, Tower 11, Avenue 5, No. 8**

**Jalan Kerinchi, Kuala Lumpur, Malaysia 59200**

(Address of principal executive offices) (Zip code)

**(908) 517-7330**

(Registrant's telephone number, including area code)

**Cyclacel Pharmaceuticals, Inc.**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | BGMS | The Nasdaq Capital Market |
| Preferred Stock, $0.001 par value | BGMSP | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**<u>Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</u>**

 ****

***Resignation of Independent Director***

On September 19, 2025, Mr. Kwang Fock Chong, an independent director on the Board of Directors (the "Board") of Bio Green Med Solution Inc. (the "Company") provided notice of his resignation from the Board. Mr. Chong's resignation was not the result of any disagreement between Mr. Chong and the Company on any matter relating to the Company's operations, policies or practices. In connection with Mr. Chong's departure, he will not be eligible to receive any severance benefits or any performance based bonus compensation for the 2025 partial year.

 ****

***Appointment of Independent Director***

Effective as of September 23, 2025, the Board appointed Ms. Soon Ping ("Zara") Pappas as an independent director to fill the vacancy.

Ms. Soon Ping ("Zara") Pappas, aged 34, brings more than 10 years of business and medical management experience to her new role on the Board. As a licensed and registered Occupational Therapy Assistant in the State of New York, Ms. Pappas has worked as a traveling therapist on Long Island, New York since 2023. Prior to that Ms. Pappas worked as an International Marketing Coordinator where she assisted in the planning, execution, and monitoring of international marketing campaigns across digital, print, and social media channels and worked with public relations, events, and operations teams to align international marketing with guest experiences. Ms. Pappas earned an Associate's Degree in Applied Science from Suffolk Community College (New York) in 2024 (Dean's List) and a Certificate in Business Studies from Segi College, Kuala Lumpur, Malaysia in 2010. Ms. Pappas is fluent in English, Mandarin, Cantonese, and Bahasa Melayu.

There is no arrangement or understanding pursuant to which Ms. Pappas was appointed to the Board and, further, Ms. Pappas has no direct or indirect material interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Board has determined to compensate Ms. Pappas in the amount of $1,000.00 per month for her service on the Board.

Pursuant to Nasdaq Listing Rule 5605(b)(1), a majority of the Board must be comprised of independent directors as defined in Nasdaq Listing Rule 5605(a)(2). Following the appointments of Ms. Pappas, the Board currently consists of five directors of which three are considered independent directors.

 ****

***Board Approval of Committee Assignments***

● *Audit Committee* — Inigo Angel Laurduraj (Chair); Soon Ping ("Zara") Pappas; and Dr. Satis Waran Nair Krishnan

● *Compensation and Organization Committee* — Soon Ping ("Zara") Pappas (Chair); Inigo Angel Laurduraj; and Dr. Satis Waran Nair Krishnan

● *Nominating and Governance Committee* — Dr. Satis Waran Nair Krishnan (Chair), Soon Ping ("Zara") Pappas and Inigo Angel Laurduraj

The Board also determined that each of Inigo Angel Laurduraj, Dr. Satis Waran Nair Krishnan and Soon Ping ("Zara") Pappas also satisfy the additional requirements of financial literacy and audit committee independence for audit committee service under the applicable rules and regulations of the SEC and the listing standards of Nasdaq.

**<u>Item 9.01. Financial Statements and Exhibits.</u>**

(d) *Exhibits.*

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit** |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: September 25, 2025 | **Bio Green Med Solution, Inc.** | **Bio Green Med Solution, Inc.** |
|  | By: | */s/ Datuk Dr. Doris Wong Sing Ee* |
|  | Name: | Datuk Dr. Doris Wong Sing Ee |
|  | Title: | Chief Executive Officer and Executive Director |

---